Category Archives: Stemson Therapeutics

Interview with Stemson CEO Geoff Hamilton

I have covered Stemson Therapeutics (San Diego, USA) and its founder Alexey Terskikh (see interview) since 2015. My last post on the company was updated in 2020 when they raised $7.5 million from Fortunis Capital and Allergan.

Since then, Stemson raised another $15 million in series A funding, courtesy of AbbVie (which acquired Allergan in 2020).

Geoff Hamilton

Stemson Therapeutics’ CEO is Geoff Hamilton. In July 2021, he  wrote an interesting post on Linkedin titled “Stemson Therapeutics is working to make hair loss a problem of the past.” It was interesting to read about the origin of the name “Stemson” (portmanteau of “Stem” and “Samson”).

Key section:

Per Mr. Hamilton, curing hair loss is inordinately complex and will involve a multi-disciplinary approach, including:

  • Cellular reprogramming.
  • Biomaterial engineering.
  • Tissue engineering.
  • Machine learning and analysis of biological data.
  • Robotic transplantation solutions.

In a recent article, Dr. Cenk Sumen (Stemson’s Chief Technology Officer) discussed other difficulties. He stated that companies such as Stemson that are working on induced pluripotent stem cell (iPSC) therapies face problems getting tailored equipment for automation.

Earlier today, San Diego based “Market Podcast” published an interview with Mr. Hamilton on YouTube. Thanks to reader “Jan Miedza” for notifying us and even posting the first comment to that video.

From the interview, it is clear that Stemson is still years away from getting a product to market. They are yet to even start human clinical trials. However, the company is professional, well funded and supported by biopharmaceutical industry behemoth AbbVie. They have hired world class scientists, bioengineers, bioinformaticians and more.

Moreover, Dr. Terskikh’s research has already been going on for over a decade (including in Russia). Also of note, Dr. Hamilton mentions several times how biotechnology and stem cell research today is significantly ahead of where it was just a decade ago. His company’s progress is benefitting from these recent technological advances.

Alexey Terskikh and Stemson Therapeutics

I first covered the groundbreaking work of Sanford Burnham’s Dr. Alexey Terskikh in 2015. Two years later, I interviewed Dr. Terskikh with the help of reader questions. It was a lengthy and highly interesting question and answer session. The doctor’s main issue at the time was funding.

A few months ago, Dr. Teskikh provided an excellent update on his hair loss research. Key quote from that interview:

“Instead of embryonic stem cells, which are difficult to obtain, our method now uses induced pluripotent stem cells (iPSC), which are derived from a simple blood draw or skin sample. iPSCs allow us to create an unlimited supply of cells to grow hair. Not having enough hair is one reason current transplants don’t work, so this is a critical advance….We’ve found a solution—3D biodegradable scaffolds—and partnered with leading scientists in the field to advance our project. The scaffold allows us to control the number of cells transplanted, their direction and where they are placed.”

Dr. Terskikh also said that as of 2018, he had formed a company to move this research and technology forward. He did not name the company or the “great team” of experts that he had assembled.

Stemson Therapeutics

Earlier today, a reader by the name of “Gabriel” sent me a Tweet (now removed, but I pasted the content below) from three weeks ago. It was missed by most people.

“Great breakfast meeting at @EstanciaLaJolla with hair restoration surgery colleague Dr Alan Bauman from Boca Raton. Excited to be the medical directors for Stemson Therapeutics, a new biotech company here in La Jolla developing groundbreaking permanent solutions for hair loss.”

— Dr. Richard Chaffoo

No mention of Dr. Alexey Terskikh in there, but….

It seems like Stemson Therapeutics LLC was registered in California in 2017 by Dr. Terskikh! Also, Dr. Terskikh is based in La Jolla (San Diego), and the Tweet above also mentions La Jolla.

Note that there is also a Stemson Therapeutics Corporation that is involved in the hair growth sector.

This looks like excellent news, even if it may take a few years before fruition.

Unless Trump issues an executive order that Phase 2 and Phase 3 trials are unnecessary :-)

Although, in this case, if the biological material and lab processes are entirely autologous… maybe portions of human trials can be rushed or skipped?